

## A Sensitive New Method for Clinically Monitoring Cytarabine Concentrations at the DNA level in Leukemic Cells

Takahiro Yamauchi\*, and Takanori Ueda

*First Department of Internal Medicine, University of Fukui,*

23 Shimoaizuki, Matsuoka, Fukui, 910-1193, Japan

**Running Title:** Measurement of DNA-incorporated ara-C *in vivo*

**\*Corresponding author:**

Dr. Takahiro Yamauchi,

Tel.: +81-776-61-3111,

Fax: +81-776-61-8109,

e-mail: [tyamauch@fmsrsa.fukui-med.ac.jp](mailto:tyamauch@fmsrsa.fukui-med.ac.jp)

**Abbreviations:** ara-C, cytarabine or 1- $\beta$ -D-arabinofuranosylcytosine; ara-CTP, cytarabine triphosphate or 1- $\beta$ -D-arabinofuranosylcytosine triphosphate; TDM, therapeutic drug monitoring; STS, Schmidt-Thannhauser-Schneider.

**Abstract**

Cytarabine (ara-C), a major antileukemic agent, is phosphorylated in the cell to cytarabine triphosphate (ara-CTP), which then is partly incorporated into DNA. The drug incorporation into DNA poisons the extending primer against further incorporation of deoxyribonucleotides including dCTP, ultimately inhibiting DNA synthesis. While intracellular ara-CTP concentration has been found to predict clinical outcome, cytotoxicity *in vitro* is determined primarily by the extent of drug incorporation into DNA. However, clinically appropriate quantitation methods for ara-C at the DNA level have not been available. We developed a sensitive new method for monitoring ara-C incorporated into DNA *in vivo*. After DNA from leukemic cells was fractionated using the Schmidt-Thannhauser-Schneider method, it was degraded to constituent nucleosides to release ara-C, which was isolated from the nucleosides using HPLC and then measured by radioimmunoassay. Recovery for DNA fractionation, ara-C release by degradation, and ara-C isolation were  $92.0 \pm$

6.4%,  $90.7 \pm 9.4\%$ , and  $98.5 \pm 1.4\%$ , respectively. The method was found to determine ara-C incorporation into DNA of ara-C-treated HL60 cells *in vitro* with minimal interassay variation. The values determined were compatible with those determined by scintillation counting in parallel experiments using tritiated ara-C. Our method could be used to monitor DNA-incorporated ara-C concentrations during ara-C therapy, together with plasma ara-C and intracellular ara-CTP concentrations. ara-C incorporation into DNA appeared to be associated with intracellular retention of ara-CTP or persistence of plasma ara-C. Thus, the present method is sensitive, accurate, precise, and may permit therapeutic drug monitoring at the DNA level for better individualization of antileukemic regimens.

**Key Words:** Cytarabine; DNA incorporation; Cytarabine triphosphate; Acute leukemia; TDM; Individualization.

## 1. Introduction

ara-C, a pyrimidine nucleoside analogue, is among the most effective anticancer agents for treatment of acute leukemia [1-3]. The drug offers flexibility of use including doses at 3 to 10 mg/m<sup>2</sup> (low dose), 70 to 100 mg/m<sup>2</sup> (regular dose), and 1 to 3 g/m<sup>2</sup> (high dose) more than a 1000-fold range [3-6]. Mechanisms of bioactivation and action are uniform regardless of dose. After being transported into leukemic cells, ara-C is phosphorylated to ara-C 5'-monophosphate and then to ara-C triphosphate (ara-CTP) [7, 8]. A small portion of this ara-CTP is incorporated as a monophosphate into DNA strands during the S phase of the cell cycle [9, 10]. The drug incorporation into DNA poisons the extending primer against further incorporation of deoxyribonucleotides including dCTP, ultimately inhibiting DNA synthesis [7-10]. Therefore, both intracellular ara-CTP and DNA-incorporated ara-C are metabolites critical to the drug's action [7-10].

In *in vitro* studies, both intracellular ara-CTP and DNA-incorporated

ara-C correlated with the cytotoxic effect of ara-C [7-12]. However, the correlation between ara-C incorporated into DNA and cell death was more significant than that between ara-CTP and cytotoxicity [9-10, 13]. Incorporation into DNA is also critical to the cytotoxic activity of fludarabine and gemcitabine [14], suggesting general importance of interactions between DNA and nucleoside analogues. Clinically observed therapeutic efficacy correlated closely with intracellular ara-CTP during high-dose ara-C treatment [15-20]. At a regular dose, we developed a sensitive method and confirmed that the metabolite ara-CTP was crucial to therapeutic outcome [21-23]. As for DNA-incorporated ara-C, one report described an assay method and its use to monitor ara-C at the DNA level in the clinic [24]. Yet, no studies have been conducted subsequently, reflecting need for more suitable *in vivo* monitoring methods. Therefore, DNA-incorporated ara-C measurement has not yet been evaluated for clinical efficacy despite its critical role for *in vitro* cytotoxicity.

To determine the clinical significance of DNA-incorporated ara-C, a better method is needed for monitoring ara-C concentrations at the DNA level

accurately and sensitively in clinical samples. Ideally the method would allow simultaneous measurement of intracellular ara-CTP and plasma ara-C.

In the present study we developed a sensitive new method for monitoring ara-C incorporated into DNA *in vivo*. The procedure included fractionation of DNA from leukemic cells (step 1), degradation of DNA to nucleosides to release ara-C (step 2), isolation of ara-C using HPLC (step 3), and measurement of ara-C by radioimmunoassay (step 4). The present study focused first on validation of recovery for each step of the assay procedure. Next, accuracy and precision of the method were confirmed using cultured leukemic cells *in vitro*. Last, clinical utility was demonstrated by applying the method to monitoring ara-C concentrations within the DNA of peripheral leukemic blasts obtained from patients receiving ara-C.

## **2. Materials and Methods**

### *2.1. Chemicals and reagents*

ara-C, bacterial alkaline phosphatase (EC 3.1.3.1), snake venom

phosphodiesterase (EC 3.1.4.1), and DNase I (EC 3.1.21.1) were purchased from Sigma. [5-<sup>3</sup>H] ara-C (30 Ci/mmol), [methyl-<sup>3</sup>H] thymidine (20 Ci/mmol), [5-<sup>3</sup>H] uridine (20 Ci/mmol), and [thymidine-methyl-<sup>3</sup>H]-DNA (0.2 μCi/μg) were purchased from Daiichi Pure Chemicals. Tetrahydrouridine, a cytidine deaminase inhibitor, was obtained from Calbiochem-Novabiochem. Charcoal was purchased from J. T. Baker Chemical. Anti-ara-C serum was kindly supplied by Daiichi Pure Chemicals. This antiserum did not cross-react with phosphorylated forms of ara-C, uracil arabinoside, cytidine, or deoxycytidine [25]. All other chemicals were of analytical grade.

### *2.2. Preparation of leukemic cells*

Human leukemia HL-60 cells were cultured in RPMI1640 media with 10% heat-inactivated fetal calf serum. The cells ( $2 \times 10^6$ /ml, 10 ml) were incubated with various concentrations of ara-C for the time periods indicated at 37°C. Cells then were washed twice with PBS and centrifuged (500 X g, 5 min, 4°C) to collect the cell pellet.

### *2.3. DNA fractionation from cells*

To fractionate DNA from the cell pellet, the classical STS method was used with slight modification [26-28]. The cell pellet described above was added to 30  $\mu$ l of 15% perchloric acid in a microcentrifuge tube. The sample then was vortexed, cooled in an ice bath for 15 min, and centrifuged (15000 X *g*, 30 sec, 4°C). The supernatant (acid-soluble fraction) was discarded, while the precipitate was obtained as the acid-insoluble fraction. To solubilize the RNA, the acid-insoluble fraction was resuspended in 100  $\mu$ l of 0.4 N KOH and kept at room temperature for 4 h. The sample then was mixed with 100  $\mu$ l of 5% perchloric acid and 20  $\mu$ l of 4 N HCl, followed by centrifugation (15000 X *g*, 30 sec, 4°C). After removal of the supernatant (RNA), the precipitate was mixed with 100  $\mu$ l of 5% perchloric acid, and then heated at 92°C for 20 min to solubilize the DNA. After centrifugation (15000 X *g*, 30 sec, 4°C), the supernatant was isolated as DNA while the precipitate (protein) was discarded.

To assess DNA fractionation, a pellet of HL 60 cells ( $1 \times 10^7$  cells) mixed with 10  $\mu$ l of [thymidine-methyl- $^3\text{H}$ ]-DNA underwent extraction of the acid-insoluble fraction and the subsequent fractionation of DNA. Radioactivity



of the fractionated DNA was compared with that of the DNA mixed with the cell pellet. To further assess the fractionation procedure, cells ( $2 \times 10^6$ /ml, 10 ml) were incubated with 20  $\mu$ l of [methyl<sup>3</sup>-H]-thymidine or <sup>3</sup>H-uridine for 5 h at 37°C. The cell pellet was subsequently fractionated into DNA, RNA, and protein, and radioactivity of each fraction was measured.

#### *2.4. ara-C release by degradation of DNA to nucleosides*

To release ara-C from DNA, the DNA was degraded to the corresponding nucleosides. The DNA fraction described above was once added to 70  $\mu$ l of 1N KOH, vortexed, and centrifuged (15000 X g, 30 sec, 4°C) to obtain the supernatant as the neutralized DNA. The neutralized DNA solution then was mixed with 300  $\mu$ l of 1 M Tris, 5  $\mu$ l of 10 mM CaCl<sub>2</sub>, 5  $\mu$ l of 10 mM MgCl<sub>2</sub>, 250 U of DNase I, 60  $\mu$ g of phosphodiesterase, 10 U of alkaline phosphatase, and 10  $\mu$ l of 1mg/ml tetrahyrdouridine. This mixture (pH 8) was incubated for 12 h at 42°C to digest the DNA to nucleosides.

To confirm degradation, HL 60 cells ( $2 \times 10^6$ /ml, 10 ml) were incubated with an aliquot of tritiated ara-C for 5 h at 37 °C, followed by fractionation of

DNA. To separate ara-C, the DNA sample was spotted on a TLC sheet (POLYGRAM CEL 300 UV<sub>254</sub>, 20 cm x 20 cm x 0.1mm, Machery-Nagel) before or after the degradation procedure, and developed by a 2-propanol: ethyl acetate: water (2:2:1) solvent for 3 h. Radioactivity of ara-C released from DNA after degradation was compared with that of ara-C-containing DNA before degradation.

#### *2.5. ara-C isolation using HPLC*

To isolate ara-C from other nucleosides, HPLC was employed. Nucleosides obtained as described above were injected onto a cation-exchange column (Partisil 10 SCX, 250 mm length x 4.6 mm inside diameter; Whatman) and eluted with 0.01 M ammonium formate (pH, 3.0) at a constant flow rate of 1.5 ml/min, at ambient temperature. ara-C was identified by its retention time (15.5 min) at 254 nm. The ara-C fraction was collected from 13 min to 18 min for a 5-min interval, and then was freeze-dried overnight.

#### *2.6. ara-C measurement using radioimmunoassay*

To measure ara-C concentration, radioimmunoassay was carried out as

previously described [21, 25]. This was a competitive reaction between tritiated ara-C and unlabeled ara-C for binding the antiserum. Briefly, the ara-C fraction obtained above (unlabeled, unknown for its concentration) was dissolved in 400  $\mu$ l of 0.01 M phosphate buffer containing 0.5% bovine serum albumin and 0.9% NaCl (pH 7.4), 100  $\mu$ l of anti-ara-C serum, and 100  $\mu$ l of diluted tritiated ara-C (0.05  $\mu$ Ci). The mixture was incubated for 3 h at 37°C to allow competition between the labeled and the unlabeled for binding the antibody. To separate the bound and free ara-C, the sample was added to 1 ml of dextran-coated charcoal (100 mg of dextran and 1000 mg of charcoal per 100 ml of the phosphate buffer above), cooled for 30 min at 4°C, and centrifuged (15000 X g, 30 sec, 4°C). The supernatant (the antibody-bound ara-C) was isolated, and its radioactivity was counted on the following day. The ara-C concentration of the sample was extrapolated in the standard curve that was drawn simultaneously using 10 independent known concentrations of ara-C. The lower limit of quantitation for the radioimmunoassay was 0.1 pmol.

### *2.7. Drug monitoring at the DNA level in the clinic*

Blood samples were obtained with informed consent from four leukemic patients receiving ara-C. The patients were diagnosed with leukemia or leukemic transformation of myelodysplastic syndrome by standard criteria with bone marrow examination. All were refractory or relapsed. In two patients (Nos. 3 and 4), plasma ara-C and intracellular ara-CTP concentrations were monitored simultaneously. Each blood sample was placed in heparinized tubes containing tetrahydrouridine at a final concentration of 0.1 mM, layered over Ficoll-Hipaque, and centrifuged (500 X g, 30 min, room temperature) to separate plasma and leukemic cells [29, 30]. Plasma ara-C concentration was determined using the radioimmunoassay described above [21, 25]. Blasts were washed twice with PBS and then centrifuged (500 X g, 5 min, 4°C) to pellet the cells. The pellet ( $2 \times 10^7$  cells) was divided into acid-soluble (supernatant) and acid-insoluble (precipitate) fractions by adding 30  $\mu$ l of 15% perchloric acid. The acid-insoluble fraction was used to measure ara-C incorporated into DNA as described above. The acid-soluble fraction was used to measure intracellular ara-CTP as previously reported [21]. Briefly, the

acid-soluble fraction was neutralized with KOH and applied to an ion-exchange column (TSK gel DEAE-2 SW, 250 mm length x 4.6 mm inside diameter; TOSOH). Elution was performed using 0.05 M Na<sub>2</sub>HPO<sub>4</sub> (pH 6.9) - 20 % acetonitrile at a constant flow rate of 0.7 ml/min, at ambient temperature. ara-CTP was monitored spectrophotometrically at 269 nm, fractionated, and freeze-dried overnight. After ara-CTP obtained was dephosphorylated enzymatically, the resulting ara-C was measured using the radioimmunoassay described above (Fig. 1).

#### *2.8. Measurement of DNA-incorporated ara-C and intracellular ara-CTP using tritiated ara-C*

To verify the present method, cultured HL 60 cells or primarily obtained leukemic cells ( $2 \times 10^6$ /ml, 10 ml) were incubated with tritiated ara-C in parallel experiments. Cells then were washed twice with PBS, and centrifuged (500 X g, 5 min, 4°C). The pellet was divided into acid-soluble and acid-insoluble fractions by adding 30 µl of 15% perchloric acid. DNA was fractionated from the acid-insoluble fraction using the STS method, while ara-CTP was isolated

from the acid-soluble fraction using HPLC as described above. Radioactivity of each metabolite was counted on the following day.

### *2.9. Statistical analyses*

All statistical analyses were performed with Microsoft Excel 2003 (Microsoft Corporation). All graphs, linear regression lines, and curves were generated using GraphPad Prism (version 4.0; GraphPad Software).

## **3. Results**

### *3.1. Recovery in the assay steps*

Recovery was evaluated for the steps of DNA fractionation, ara-C release, and ara-C isolation. To assess recovery at the step of DNA fractionation, the pellet of HL 60 cells was mixed with tritiated DNA, followed by the DNA fractionation procedure described in Materials and Methods. Radioactivity of DNA fractionated from the mixture was equal to that present in the tritiated DNA added to the cell pellet (Table 1). To further confirm the

completeness of the fractionation procedure, the cells were incubated with tritiated thymidine or uridine, followed by fractionation into DNA, RNA, and protein as described in Materials and Methods. Radioactivity in each fraction demonstrated clear separation and excellent recovery of DNA (Table 1).

To assess recovery at the step of ara-C release, cells were incubated with tritiated ara-C to allow its incorporation into DNA. The DNA then was fractionated from the cells and ultimately degraded to nucleosides as described in Materials and Methods. TLC revealed that radioactivity of ara-C released from DNA after degradation was compatible with that of the ara-C-bearing DNA before degradation (Table 1).

To assess recovery at the step of ara-C isolation, a mixture of tritiated ara-C and standard deoxyribonucleosides was eluted by HPLC. ara-C (retention time; 15.5 min) was clearly separated from the other nucleosides (retention times; uracil arabinoside; 2.3 min, thymidine; 2.7 min, 2'-deoxyguanosine; 6.5 min, 2'-deoxycytidine; 23.3 min, 2'-deoxyadenosine; 34.8 min), and subsequently fractionated, lyophilized overnight, and recovered.

Radioactivity of the ara-C recovered was equal to that of the ara-C added to the mixture (Table 1). Thus, recovery was excellent at each step in the present assay procedure, strongly supporting its practicability.

### *3.2. Measurement of DNA-incorporated ara-C in biologic samples*

To evaluate accuracy, precision, and sensitivity of measurements in biologic samples, DNA-incorporated ara-C was quantitated in ara-C-treated HL 60 cells using our assay. Figure 2 demonstrates that DNA-incorporated ara-C increased both concentration- and time-dependently, reaching a plateau at concentrations of 5 to 10  $\mu\text{M}$  or at incubation periods of 4 to 6 h. As for interassay variability, the coefficient of variation was approximately 30% at each concentration (Table 2), suggesting appropriate precision despite the multistep nature of the method and the use of biologic materials. The lower limit of quantitation, defined as the lowest concentration that gave a coefficient of variation less than 50%, was 1 pmol/ $1 \times 10^7$  cells. This limit permitted sufficient sensitivity to detect DNA-incorporated ara-C yielded by incubation with ara-C at 0.5  $\mu\text{M}$  (Fig. 2A), a concentration near the plasma concentration obtained



during continuous infusion of conventional-dose ara-C [23]. To evaluate accuracy of the method, ara-C concentrations at the DNA level measured by the present method were compared with those obtained using tritiated ara-C in the same experimental setting (Figs. 2A and B). ara-C concentrations obtained by these two methods were quite similar to each other, with statistically significant correlation values (Figs. 2A and B, inset). Thus, the present assay method was precise, accurate, and sensitive for quantitation of DNA-incorporated ara-C in biologic materials, strongly supportive of clinical applicability.

### *3.3. Monitoring ara-C at the DNA level in the clinic*

To confirm clinical utility of the present method, TDM was conducted to determine ara-C incorporation into DNA *in vivo* in primarily obtained leukemic cells from patients receiving ara-C. Table 3 presents DNA-incorporated ara-C concentrations during intermediate- and high-dose ara-C administration in four leukemic patients. ara-C concentrations varied widely among patients, doses, and sampling time points. Figures 3A and C present concentration-time

curves in two patients (Nos. 3 and 4), indicating comprehensive TDM of ara-C at the plasma, the cellular, and the DNA levels. To confirm these monitored values, leukemic blasts obtained from the same two patients prior to chemotherapy were incubated *in vitro* with tritiated ara-C. DNA-incorporated ara-C and intracellular ara-CTP concentrations were measured by scintillation counting (Figs. 3B and D). Concentrations of both metabolites monitored in the clinic (Fig. 3A for patient 3, Fig. 3C for patient 4) were in the same range of those obtained in the culture media with added tritiated ara-C (Fig. 3B for patient 3, Fig. 3D for patient 4), supporting accuracy of this TDM. Thus, the present assay method was capable of measuring ara-C concentration at the DNA level in leukemic cells from patients receiving ara-C chemotherapy. The method provided measurements of intracellular ara-CTP and plasma ara-C concentrations at the same time (Figs. 1 and 3).

#### **4. Discussion**

We presently described and validated a sensitive new method for monitoring ara-C concentrations at the DNA level in leukemic cells *in vivo*. Recovery at each step of the procedure was excellent (Table 1). The method was sensitive for measuring DNA-incorporated ara-C in cultured leukemic cells treated with 0.5 to 10  $\mu\text{M}$  ara-C *in vitro* (Fig. 2). Values obtained were accurate, agreeing with those determined by scintillation counting using tritiated ara-C in parallel experiments (Fig. 2, inset). Precision was confirmed by a minimal interassay variation despite the multistep nature of the process and the use of the biologic materials (Table 2). The method was applied to monitoring DNA-incorporated ara-C concentrations in leukemic blasts from patients being treated with ara-C (Table 3, Fig. 3). Monitored values were verified by comparison with values determined in the same sample of the patients' cells before treatment using tritiated ara-C *in vitro* (Fig. 3). The method adapted easily to simultaneous measurement of intracellular ara-CTP and plasma ara-C (Figs. 1 and 3). Thus, the present assay was accurate, precise, and sensitive for clinical monitoring of ara-C concentrations at the DNA level.

A similar method developed by Spriggs et al. for quantitation of ara-C incorporated into DNA of leukemic cells [24] also used DNA fractionation from cells, HPLC separation of ara-C from DNA, and ara-C measurement using radioimmunoassay. The major difference between their method and ours involved DNA fractionation. Spriggs used enzymatic isolation with ethanol precipitation, while we employed the classical STS method. The former was developed simply to isolate intact DNA from the cell, while the latter was developed for quantitation of DNA content in the entire cell [26-28, 31]. This suggests that the STS method should achieve better recovery of DNA from the cell than the enzymatic method [32]. Adoption of the STS fractionation should enable our method to obtain more DNA from samples and accurately measure lower concentrations of DNA-incorporated ara-C. Our method also may be better suited to simultaneous measurement of intracellular ara-CTP and plasma ara-C concentrations. Thus, our method was used to monitor drug concentrations at the DNA level over time during ara-C therapy; in contrast, no data obtained using the previous method have been reported since the initial

study.

The present assay method monitored ara-C concentrations at the DNA level in circulating blasts from leukemic patients receiving ara-C (Table 3, Figs 3A and C). In patient 3 (Fig. 3A), concentrations of DNA-incorporated ara-C, intracellular ara-CTP, and plasma ara-C were greatest at the end of the infusion. All three forms of ara-C decreased gradually, and fell below the quantitation limit by 8 h after the infusion. Elimination of DNA-incorporated ara-C appeared to be slower than that of intracellular ara-CTP, in agreement with previous *in vitro* results in which DNA-incorporated ara-C was more persistent than intracellular ara-CTP [13, 33, 34]. In patient 4 (Fig. 3C), both plasma ara-C and intracellular ara-CTP were maintained longer than in patient 3. This appears to reflect our previous finding that maintenance of plasma ara-C was necessary for retention of ara-CTP in leukemic cells [22, 23]. Unlike that in patient 3, the DNA-incorporated ara-C concentration in patient 4 was even increased between 5 and 8 h after the end of the infusion (Fig. 3C). This might be attributed to prolonged retention of ara-CTP in cells, since ara-C

incorporation into DNA requires intracellular ara-CTP formation [35, 36]. Moreover, as maintenance of plasma ara-C is necessary for ara-CTP formation [22, 23], relatively slow elimination of plasma ara-C in patient 4 might be primarily responsible for prolonged incorporation of ara-C into DNA. Thus, DNA incorporation of ara-C might depend in part on intracellular retention of ara-CTP or persistence of plasma ara-C.

Intracellular ara-CTP concentrations in patient 3 (Fig. 3B) were similar to those determined in cultured HL 60 cells (30 – 300 pmol/ $1 \times 10^7$  cells) [34]. However, ara-C concentrations at the DNA level in patient 3 (1 to 10 pmol/ $1 \times 10^7$  cells, Fig. 3B) were much lower than those of HL 60 cells (10 to 80 pmol/ $1 \times 10^7$  cells, Fig. 2A). Because the extent of ara-C incorporation into DNA is cell-cycle dependent [7, 8, 11, 12, 35], greater ara-C incorporation into DNA of cultured cells may reflect a larger S-phase fraction than that in patient's circulating blasts. In relapsed leukemia, various mechanisms of ara-C resistance such as the increases in DNA polymerases [36] and in DNA exonuclease activity [37, 38] also may reduce DNA incorporation of the drug

despite intracellular retention of ara-CTP. If so, the ara-C concentration at the DNA level may not always be proportional to the intracellular ara-CTP concentration and therefore not be entirely predictable from plasma or cellular pharmacokinetics. Moreover, the DNA-incorporated ara-C concentration in patient 4 increased between 5 and 8 h after ara-C infusion while no further incorporation was observed at 5 h in patient 3 (Figs. 3A&C). In addition to the pharmacokinetic consideration above, the ara-C concentration at the DNA level in patient 4 may not have been fully sufficient to terminate DNA chain elongation, thus allowing the drug to be incorporated further into the blasts' replicating DNA. This also suggested a possibility that individual patients may have different target drug concentrations at the DNA level for maximal inhibition of DNA synthesis. Accordingly, DNA-incorporated ara-C may be worthy of pharmacokinetic evaluation as an independent parameter for prediction of therapeutic outcome with ara-C.

A combination of regular-dose ara-C given for 7 days with daunorubicin given for 3 days has been a standard induction therapy for the last 20 years.

This regimen achieves complete remission rates of over 70% in adult patients with acute myeloid leukemia [1-3]. However, the remissions are not durable, and long-term survivors account for only 30% to 40% of patients. Because achievement of complete remission is indispensable for long-term survival and cure, reinforcement of induction therapy may improve results in terms of both rate and quality of the remission. Quality or depth of remission may differ among patients responding to the same induction regimen because their leukemic cells vary in drug sensitivity. As ara-C is the key drug in remission induction therapy, quality of remission well may depend on sensitivity of the cells to ara-C. Therapeutic outcome with ara-C has been closely associated with intracellular pharmacokinetics as opposed to the plasma ara-C concentration [15-20, 39, 40]. However, ara-C-induced cytotoxicity *in vitro* has been found to be determined primarily by the extent of incorporation of ara-C into DNA [13]. If this also is the case in the clinical setting, ara-C therapy may be individualized best according to the pharmacokinetics not only of intracellular ara-CTP but also of DNA-incorporated ara-C. We have developed sensitive



techniques for clinically monitoring intracellular ara-CTP [21] and now also DNA-incorporated ara-C (Fig. 1). Therapy for leukemia thus may be individualized based on TDM at the DNA level for ara-C.

### **Acknowledgments**

This work was supported in part by a Grant-in-Aid for Scientific Research of Japan (C-2, 2003), Grants from the Japan Research Foundation for Clinical Pharmacology (J040000170, J040000189), and a Grant from Magobei Memorial Foundation for Medicine (J040000585).

We thank Ms. Mari Yamagishi for her secretarial assistance.

## Legends

Fig. 1. Scheme for clinical monitoring of ara-C and metabolites. Plasma ara-C, intracellular ara-CTP, and DNA-incorporated ara-C can be measured simultaneously in one blood sample.

Fig. 2. Measurement of DNA-incorporated ara-C in biologic samples *in vitro*. HL 60 cells were incubated with various concentrations (0.5  $\mu\text{M}$ , 1  $\mu\text{M}$ , 2  $\mu\text{M}$ , 5  $\mu\text{M}$ , and 10  $\mu\text{M}$ ) of ara-C for 6 h (A), or with 10  $\mu\text{M}$  ara-C for the indicated time periods (2 h, 4 h, and 6 h) (B). ara-C incorporated into DNA was measured using the present assay method ( $\bullet$ ). Alternatively, the cells were incubated with tritiated ara-C in the same experimental setting, and ara-C incorporated into DNA then was determined by scintillation counting (o). Inset: DNA-incorporated ara-C concentrations were compared between these two measurements for each experiment. Ordinate, DNA-incorporated ara-C measured by the present method ( $\text{pmol}/1 \times 10^7 \text{ cells}$ ). Abscissa,

DNA-incorporated ara-C measured by scintillation counting (pmol/ $1 \times 10^7$  cells).

$r^2 = 0.99$ , slope = 1.16,  $P < 0.0001$  for Fig. 2(A) inset,  $r^2 = 0.99$ , slope = 1.12,  $P < 0.0001$  for Fig. 2(B) inset.

Fig. 3. TDM during ara-C therapy. (A) and (C), Concentration-time curves of plasma ara-C (\*), intracellular ara-CTP (o), and DNA-incorporated ara-C (●). Leukemic patients (A; Patient 3, acute myeloid leukemia, M5b, C; Patient 4, plasma cell leukemia) were treated with 1-h intravenous infusion of  $1 \text{ g/m}^2$  ara-C, and blood samples were collected at the indicated time points (before the treatment, 0 h, 1 h, 3 h, 5 h, and 8 h after the end of the infusion). Concentrations of ara-C incorporated into genomic DNA of leukemic cells (●) were quantitated using the present method. Concentrations of plasma ara-C (\*) and intracellular ara-CTP of leukemic cells (o) were measured simultaneously. (B) and (D), DNA-incorporated ara-C and intracellular ara-CTP concentrations in pretreatment leukemic cells (B; Patient 3, D; Patient 4) exposed *in vitro* to ara-C. Leukemic blasts were obtained prior to

chemotherapy from each patient, resuspended in fresh media, and incubated for 6 h with various concentrations (1  $\mu\text{M}$ , 2  $\mu\text{M}$ , 5  $\mu\text{M}$ , and 10  $\mu\text{M}$ ) of tritiated ara-C. Intracellular ara-CTP (o) and DNA-incorporated ara-C (●) were measured by scintillation counting.

## References

- [1] Newland A. Progress in the treatment of acute myeloid leukemia in adults. *Int J Hematol* 2002;76 (Suppl. 1):253-8.
- [2] Winton EF, Langston AA. Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukaemia in adults. *Semin Oncol* 2004;31 (2 Suppl. 4):80-6.
- [3] Ferrara F. Unanswered questions in acute myeloid leukaemia. *Lancet Oncol* 2004;5:443-50.
- [4] Ossenkoppele GJ, Wijermans PW, Nauta JJ, Huijgens PC, Langenhuijsen MM. Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: In vivo and in vitro cytotoxicity. *Eur J Cancer* 1991;27:842-5.
- [5] van Prooijen HC, Dekker AW, Punt K. The use of intermediate-dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. *Br J Haematol* 1984;57:291-9.
- [6] Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP.

High-dose cytosine arabinoside therapy for refractory leukemia. *Blood* 1983;62:361-9.

[7] Furth JJ, Cohen SS. Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1- $\beta$ -D-arabinofuranosylcytosine and the 5'-triphosphate of 9- $\beta$ -D-arabinofuranosyladenine. *Cancer Res* 1968;28:2061-7.

[8] Inagaki A, Nakamura T, Wakisaka G. Studies on the mechanism of action of 1- $\beta$ -D-arabinofuranosylcytosine as an inhibitor of DNA synthesis in human leukemic leukocytes. *Cancer Res* 1969;29:2169-76.

[9] Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of ara-C into DNA. *J Biol Chem* 1980;255:8997-9990.

[10] Major PP, Egan EM, Beardsley GP, Minden MD, Kufe, DW. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. *Proc Natl Acad Sci U S A* 1981;78:3235-9.

[11] Graham FL, Whitmore GF. The effect of 1- $\beta$ -D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells. *Cancer Res*

1970;30:2627-35.

[12]Graham FL, Whitmore GF. Studies in mouse L-cells on the incorporation of 1- $\beta$ -D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1- $\beta$ -D-arabinofuranosylcytosine 5'-triphosphate. *Cancer Res* 1970;30:2636-44.

[13]Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. *Blood* 1984;64:54-8.

[14]Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. *Cancer Chemother Pharmacol* 1995;36:181-8.

[15]Plunkett W, Hug V, Keating MJ, Chubb S. Quantitation of 1- $\beta$ -D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1- $\beta$ -D-arabinofuranosylcytosine therapy. *Cancer Res* 1980;40:588-91.

[16]Liliemark JO, Plunkett W, Dixon DO. Relationship of

1- $\beta$ -D-arabinofuranosylcytosine in plasma to 1- $\beta$ -D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1- $\beta$ -D-arabinofuranosylcytosine. *Cancer Res* 1985;45:5952-7.

[17]Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. *Semin Oncol* 1985;12 (Suppl. 3):20-30.

[18]Iacoboni SJ, Plunkett W, Kantarjian HM, et al. High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. *J Clin Oncol* 1986;4:1079-88.

[19]Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1- $\beta$ -D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1- $\beta$ -D-arabinofuranosylcytosine therapy. *Cancer Res* 1987;47:3005-11.

[20]Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. *J Clin Oncol* 1989;7:622-8.



- [21]Yamauchi T, Ueda T, Nakamura T. A new sensitive method for determination of intracellular 1- $\beta$ -D-arabinofuranosylcytosine 5'-triphosphate content in human materials *in vivo*. *Cancer Res* 1996;56:1800-4.
- [22]Yamauchi T, Kishi S, Kawai Y, et al. Pharmacokinetics of intracellular ara-CTP, an active metabolite of ara-C in leukemic cells from patients treated with ara-C including low-dose by a newly established assay. *Proc Am Soc Clin Oncol* 1998;17:255a.
- [23]Yamauchi T, Kawai Y, Kishi S, et al. Monitoring of intracellular 1- $\beta$ -D-arabinofuranosylcytosine 5'-triphosphate in 1- $\beta$ -D-arabinofuranosylcytosine therapy at low and conventional doses. *Jpn J Cancer Res* 2001;92:546-53.
- [24]Spriggs D, Robbins G, Ohno Y, Kufe D. Detection of 1- $\beta$ -D-arabinofuranosylcytosine incorporation into DNA *in vivo*. *Cancer Res* 1987;47:6532-6.
- [25]Shimada N, Ueda T, Yokoshima T, Oh-ishi J, Oh-oka T. A sensitive and specific radioimmunoassay for 1- $\beta$ -D-arabino-furanosylcytosine. *Cancer Lett*

1984;24:173-8.

[26]Schmidt G, Thannhauser SJ. A method for the determination of desoxyribonucleic acid, ribonucleic acid, and phosphoproteins in animal tissues. J Biol Chem 1945;161:83-9.

[27]Schneider WC. Phosphorus compounds in animal tissues, I. Extraction and estimation of desoxypentose nucleic acid and of pentose nucleic acid. J Biol Chem 1945;161:293-303.

[28]Schneider WC. Phosphorus compounds in animal tissues, III. A comparison of methods for the estimation of nucleic acids. J Biol Chem 1946;164:747-51.

[29]Ho DHW, Frei E III. Clinical pharmacology of 1- $\beta$ -D-arabinofuranosylcytosine. Clin Pharmacol Ther 1971;12:944-54.

[30]Fallon HJ, Frei E III, Davidson JD, Trier JS, Burk D. Leukocyte preparations from human blood: evaluation of their morphologic and metabolic state. J Lab & Clin Med 1962;59:779-91.

[31]Davis RW, Thomas M, Cameron J, St John TP, Scherer S, Padgett RA.

Rapid DNA isolations for enzymatic and hybridization analysis. *Methods Enzymol* 1980;65:404-11.

[32]Berneman A, Lenfant M, Lambiotte M. Incorporation of tritiated thymidine into DNA of rat liver: A critique of various evaluation methods. *Biochimie* 1975;57:773-7.

[33]Wang L-M, White JC, Capizzi RL. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology. *Cancer Chemother Pharmacol* 1990;25:418-24.

[34]Kamiya K, Uchida M, Ueda T, Nakamura T. Studies on intracellular kinetics of ara-C triphosphate in HL-60 human leukemia cells in relation to reasonable administration of ara-C. *J Jpn Soc Cancer Ther* 1990;25:1419-27.

[35]Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. *Cancer Res* 1989;49:3823-8.

- [36]Galmarini CM, Thomas X, Calvo F, et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. *Br J Haematol* 2002;117:860-8.
- [37]Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2', 2'-difluorodeoxycytidine on DNA synthesis. *Cancer Res* 1991;51:6110-7.
- [38]Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. *Int J Mol Med* 2000;5:597-604.
- [39]Ueda T, Nakamura T, Ando S, et al. Pharmacokinetics of N<sup>4</sup>-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia. *Cancer Res* 1983;43:3412-6.
- [40]Ueda T, Kamiya K, Urasaki Y, et al. Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. *Cancer Res* 1994;54:109-13.

# Table 1 Recovery at each step

Step in procedure	Radioactivity (DPM)			Recovery (%)	
1, DNA fractionation (1)	Before		After	92.0 ± 6.4	
	37194		33291		
	37732		32879		
	38260		38000		
2, DNA fractionation (2)		RNA	DNA	Protein	
	thymidine	330 (2%)	14802 (90%)	1308 (8%)	DNA (%)
		944 (6%)	13900 (92%)	306 (2%)	91.6 ± 1.6
		902 (7%)	12820 (92%)	53 (1%)	
	uridine	27563 (91%)	1102 (3%)	1848 (6%)	RNA (%)
		29766 (90%)	3055 (9%)	349 (1%)	90.0 ± 0.1
		28885 (90%)	2871 (8%)	514 (2%)	
3, ara-C release	DNA		ara-C	90.7 ± 9.4	
	2300		1864		
	2000		1995		
	2496		2281		
4, ara-C isolation	Before		After	98.5 ± 1.4	
	38200		38213		
	38380		37380		
	39324		38571		

1, A pellet of HL 60 cells mixed with tritiated DNA underwent the DNA fractionation procedure. Radioactivity of the fractionated DNA was compared with that of the DNA mixed with the cell pellet. 2, Cells were incubated with tritiated thymidine or uridine, followed by fractionation into DNA, RNA, and protein. Radioactivity of each fraction was measured. 3, Cells were incubated with tritiated ara-C, and then DNA was fractionated from the cells and subsequently degraded to nucleosides. Radioactivity of ara-C released from DNA after degradation was compared with that of ara-C-containing DNA before degradation. 4, Tritiated ara-C and standard deoxyribonucleosides were co-eluted in HPLC. ara-C was fractionated, lyophilized overnight, and recovered in 1 ml of water. Radioactivity of ara-C recovered was compared with that of ara-C applied to HPLC. Values for recovery are the means ±SD of paired samples analyzed in triplicate.

Table 2 Interassay variation for quantitating ara-C incorporated into DNA


ara-C ( $\mu\text{M}$ )	DNA-incorporated ara-C		
	Mean	SD	%CV
1	15	4.0	27.2
2	35	7.1	20.2
5	61	22.4	36.5
10	63	18.8	29.9

HL 60 cells were incubated for 6 h with the indicated concentrations of ara-C on three separate days. Concentrations of ara-C incorporated into DNA (pmol/ $1 \times 10^7$  cells) were measured using the present method. CV; coefficient of variation.



Table 3 ara-C incorporated into DNA of leukemic cells from patients receiving ara-C





Pt.	age/ gender	Diagnosis	Treatment	WBC (blasts %) ( $\mu$ /l)	Time*	DNA-incorporated ara-C (pmol/1 x 10 <sup>7</sup> cells)
1	50 / F	AML (M2) [First relapse]	1 g/m <sup>2</sup> , 1 h-iv inf	40000 (98)	1 h (day 1)	60
					2 h (day 1)	40
					3 h (day 1)	110
2	72 / F	MDS-LT [Primary refractory]	1 g/m <sup>2</sup> , 1 h-iv inf	64800 (87) 46600 (89)	5 h (day 1)	15
					5 h (day 2)	35
3	73 / M	AML (M5b) [First relapse]	1 g/m <sup>2</sup> , 1 h-iv inf	60000 (97)	0 h (day 1)	3.7
					1 h (day 1)	3
					3 h (day 1)	1.9
					5 h (day 1)	ND
					8 h (day 1)	ND
4	59/M	Plasma cell leukemia [Primary refractory]	1 g/m <sup>2</sup> , 1 h-iv inf	10000 (90)	0 h (day 1)	1
					1 h (day 1)	NE
					3 h (day 1)	3
					5 h (day 1)	8
					8 h (day 1)	27

Leukemic patients were treated with ara-C, and peripheral blasts were collected at indicated time points. Concentrations of ara-C incorporated into DNA of leukemic cells were quantitated using the present method. AML, acute myeloid leukemia; M2, M5b, subclass of leukemia by French-American-British classification; MDS-LT, leukemic transformation of myelodysplastic syndrome; WBC, peripheral white blood cell; 1 h-iv inf, intravenous infusion for 1 h; 2 h-iv inf, intravenous infusion for 2 h; NE, not evaluated; ND, not detected (below the lower detection limit). \*Sampling time points after the end of infusion.









Yamauchi T, Fig. 3